美国食品和药物管理局批准第二种通用米费普里斯顿, 增加了早产期10周的流产机会. FDA approves second generic mifepristone, boosting access for early abortion up to 10 weeks.

林业发展局核准了由Evita Solutions制作的第二个堕胎药丸Mifeprístone通用版本,供怀孕10周以内使用。 The FDA approved a second generic version of the abortion pill mifepristone, made by Evita Solutions, for use up to 10 weeks of pregnancy. 该药物阻断了孕酮以终止早孕,如果与碘甲醇结合使用,其有效率为97%。 The drug, which blocks progesterone to end early pregnancies, is 97% effective when combined with misoprostol. 批准工作于2025年9月完成,在标准监管审查之后进行,目的是增加获得服务的机会和负担能力。 The approval, finalized in September 2025, follows standard regulatory review and aims to increase access and affordability. 它立即受到反堕胎团体和共和党领导人的批评,他们称这一决定很危险,并敦促进行安全审查。 It has drawn immediate criticism from anti-abortion groups and Republican leaders, who called the decision dangerous and urged a safety review. 林业发展局认为该药物是安全和有效的,尽管对药品的分发不断施加政治压力并面临法律挑战。 The FDA maintains the drug is safe and effective, despite ongoing political pressure and legal challenges over its distribution.